Overview

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

Status:
Completed
Trial end date:
2018-12-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vascular Biogenics Ltd. operating as VBL Therapeutics
Treatments:
Bevacizumab